Navigation Links
Keryx Biopharmaceuticals Announces $55 Million Proposed Public Offering of Common Stock
Date:1/29/2013

NEW YORK, Jan. 29, 2013 /PRNewswire/ -- Keryx Biopharmaceuticals, Inc. (NASDAQ: KERX) today announced that it has commenced a $55 million underwritten public offering of shares of its common stock. In connection with this offering, Keryx expects to grant to the underwriters a 30-day option to purchase additional shares of common stock, equal to up to 15% of the number of shares of common stock sold in the offering. J.P. Morgan is acting as the sole book-running manager in the offering.   We intend to use the net proceeds from the sale of our common stock to fund pre-launch/launch inventory build-up and select pre-commercial/commercial activities related to Zerenex, and other general corporate purposes.

The securities described above are being offered by Keryx pursuant to a Form S-3 shelf registration statement (including a base prospectus) previously filed with the Securities and Exchange Commission ("SEC"). Before you invest, you should read the prospectus in the registration statement and related preliminary prospectus supplement that Keryx has filed with the SEC for more complete information about Keryx and this offering. The preliminary prospectus supplement is available for free by visiting EDGAR on the SEC's website located at www.sec.gov. Copies of the preliminary prospectus supplement and accompanying prospectus may also be obtained from the offices of J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, New York 11717 (telephone: 866-803-9204).

This news release shall not constitute an offer to sell or the solicitation of an offer to buy these securitie
'/>"/>

SOURCE Keryx Biopharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine technology :

1. Keryx Biopharmaceuticals, Inc. To Host Conference Call on Third Quarter 2012 Financial Results
2. Keryx Biopharmaceuticals, Inc. To Host Conference Call on Second Quarter 2012 Financial Results
3. Keryx Biopharmaceuticals Announces Upcoming Poster Presentation of Zerenex™ (ferric citrate) at the 49th ERA-EDTA Congress
4. Keryx Biopharmaceuticals, Inc. Announces First Quarter 2012 Financial Results
5. Keryx Biopharmaceuticals, Inc. To Host Conference Call on First Quarter 2012 Financial Results
6. Biopharmaceutical Industry Veterans Join Inspiration Biopharmaceuticals Board of Directors
7. Alder Biopharmaceuticals Receives $3.5 Million Milestone Payment from Bristol-Myers Squibb for Initiation of Phase 2 Clinical Trial of ALD518/BMS-945429 in Crohns Disease
8. Inspiration Biopharmaceuticals Announces Clinical Hold of Clinical Trials Evaluating IB1001 for the Treatment and Prevention of Bleeding in Hemophilia B
9. Inspiration Biopharmaceuticals Reports Positive Interim Results from the Accur8 Phase 2/3 Study of OBI-1 in Acquired Hemophilia A at WFH 2012 World Congress
10. Alder BioPharmaceuticals Inc. Initiates Phase 1 Clinical Study of Antibody Therapeutic Candidate for Treatment of Migraine, ALD403
11. Generex Announces Details of Investor Conference Call
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2013)... -- NxStage Medical, Inc. (Nasdaq: NXTM ), a ... it has entered into new agreements covering its supply ... the kidney care division of DaVita Healthcare Partners Inc. ... the use of products for home hemodialysis in ... a second amended and restated National Service Provider Agreement ...
(Date:5/21/2013)... 2013   Regulus Therapeutics Inc . ( NASDAQ: ... development of innovative medicines targeting microRNAs, today announced that ... Operating Officer and Executive Vice President, Finance, will present ... Healthcare Conference on Wednesday, May 29, 2013 at 3:30 ... Westin Boston Waterfront Hotel. The presentation will ...
(Date:5/21/2013)... and PHILADELPHIA , May 21, 2013 /PRNewswire/ ... new corporate image and impressive new product developments at the ... . "After ten years of unerring focus on product literature ... the need to mark the occasion," said founding director ... have some interesting developments of benefit to our clients and ...
Breaking Medicine Technology:NxStage Announces New Agreements with DaVita 2Regulus to Present at Deutsche Bank 38th Annual Healthcare Conference 2Pi2 Solutions' 10th Anniversary Heralds New Corporate Image as Platinum Sponsor of SLA PHT Meeting in Philadelphia 2Pi2 Solutions' 10th Anniversary Heralds New Corporate Image as Platinum Sponsor of SLA PHT Meeting in Philadelphia 3
... CHICAGO, Oct. 28 The non-profit Midwest Business Group ... with numerous local and national organizations, have launched a health ... personal contact to help people improve and manage health conditions. ... ) information series will run through the end of ...
... 28 Amira Pharmaceuticals, Inc. announced today that it ... a novel LPA1 antagonist, in normal, healthy subjects. ... exploring the therapeutic value of AM152, a potentially novel ... safety, pharmacodynamic (PD) and pharmacokinetic (PK) profile of this ...
Cached Medicine Technology:New 'Take Control of Your Health' Education Series to Improve Health of Chicagoans 2Amira Pharmaceuticals Announces Initiation of Phase I Clinical Trial for AM152, A Novel LPA1 Antagonist 2
(Date:5/21/2013)... Paris, France: One-year results from SOURCE XT one ... registries to-date reported today at EuroPCR 2013 show ... rates of device success for all access approaches, valve ... Study followed up 2688 consecutively enrolled patients (mean age ... valve at 93 centres in 17 countries between July ...
(Date:5/21/2013)... stent, which is a novel stent platform eluting ... the Xience Prime everolimus-eluting stent for the primary ... nine months in the results of an imaging ... BIOFLOW-II substudy used intravascular ultrasound (IVUS) and optical ... and stent apposition at nine months after treating ...
(Date:5/21/2013)... Arizona State University is seeking ... develop their ideas into solutions, products and services ... university is recruiting participants for AREA48 (Applied Regional ... provides early-stage entrepreneurs with opportunities to access human ... anyone, ASU is particularly seeking participation from retirees, ...
(Date:5/21/2013)... CA (PRWEB) May 21, 2013 According to ... to Rethink the Use of Botox,” Botox injections ... since their approval in 2002 (Go to goo.gl/8iYbD). Although it ... quite popular with men. The injection makes facial wrinkles less ... Botox injection last for about three months. This means that ...
(Date:5/21/2013)... The federal judge overseeing the litigation ... lawsuits in U.S. District Court, Northern District of Georgia, ... from Plaintiffs’ Counsel to conduct Ex Parte interviews with ... Order grants that request, and sets forth procedures under ... Medical Technology, Inc., Conserve Hip Implant Products Liability Litigation, ...
Breaking Medicine News(10 mins):Health News:Biodegradable stent proves non-inferior to drug-eluting stent 2Health News:ASU Launches Summer Program for Aspiring Entrepreneurs, Innovators and Inventors 2Health News:ASU Launches Summer Program for Aspiring Entrepreneurs, Innovators and Inventors 3Health News:ASU Launches Summer Program for Aspiring Entrepreneurs, Innovators and Inventors 4Health News:Botox – Is the World’s Most Popular Cosmetic Procedure Safe? 2Health News:Wright Hip Lawsuit News: Bernstein Liebhard LLP Notes Issuance of New Order in Federal Wright Conserve Hip Replacement Litigation 2Health News:Wright Hip Lawsuit News: Bernstein Liebhard LLP Notes Issuance of New Order in Federal Wright Conserve Hip Replacement Litigation 3
... cuts readmissions , , WEDNESDAY, May 6 (HealthDay News) -- ... airway pressure (CPAP) may help improve outcomes in patients ... CPAP is commonly used to treat sleep apnea. ... Chest , included 232 cardiac surgery patients who ...
... Former McKesson executive to lead further innovation of ... government agencies and wellness companiesBEDFORD, Mass., May 6 ... management software solutions, today announced that Bill Wisotzkey ... and design, effective immediately. Wisotzkey has more than ...
... outbreak in Mexico, the Foreign and Commonwealth Office (FCO) is advising against ... it will consider all claims for cancelled holidays to the country, scheduled ... ... (PRWEB) -- In the wake of the swine flu outbreak in Mexico, ...
... PHILADELPHIA, May 6 The Mobile Massage Team ( ... services for corporate wellness programs, promotional events, and special affairs, ... exhibitor at the 3rd Annual GlobalFit Worksite Wellness Summit ( ... 14, 2009 at The Down Town Club in Center City ...
... conference focused on promoting physical activity on college ... on connecting health care providers and the public ... infiltrating college campuses nationwide. The American College of ... On Campus," a program component to address and ...
... Against Tobacco Recognized Nationally--WASHINGTON, May 6 ... named Youth Advocates of the Year by the Campaign ... fight against tobacco. Members of REAL are being honored ... the nation,s capital tonight (May 6) along with a ...
Cached Medicine News:Health News:Casenet Names Bill Wisotzkey Vice President of Product Management and Design 2Health News:Sainsbury's Travel Insurance will Consider Claims for Cancelled Holidays to Mexico 2Health News:Sainsbury's Travel Insurance will Consider Claims for Cancelled Holidays to Mexico 3Health News:'Exercise is Medicine On Campus' Launches With National Call to Action 2Health News:'Exercise is Medicine On Campus' Launches With National Call to Action 3Health News:Campaign for Tobacco-Free Kids Honors REAL of Hawai'i As Youth Advocates of the Year 2
Jayle tying forceps, straight....
Troutman tying forceps are curved, delicate, bullet shape, with tying platforms. Flat pattern. Ultra fine platforms ideal for 10-0 or 11-0 suture material. Platforms fully meet to hold suture firmly....
Gerl titanium tying forceps has curved shanks, smooth jaws and 6 mm long tying platform. For 8-0 to 11-0 sutures....
Harms tying forceps, standard, straight with smooth jaws. For 7-0 to 9-0 sutures....
Medicine Products: